RankAlpha logo
Back to Rankings

XERS

Xeris BiopharmaB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
Current thesis
The post-earnings company release was clearly constructive: revenue grew 38% year over year, Recorlev was the main driver, gross margin improved to 87%, and Xeris produced positive net income and adjusted EBITDA while lifting the low end of 2026 revenue guidance [#8-K-2026-05-07]. Pre-print third-party estimate pages in the packet indicated revenue expectations around $80 million and roughly breakeven EPS, so the reported $83.1 million and $0.01 GAAP EPS suggest at least a modest beat versus low external expectations.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Balance-sheet flexibility is better than in earlier periods, but Xeris still carried about $221.2 million of long-term debt against $111.8 million of cash at March 31, 2026, which keeps financing and execution discipline relevant [#8-K-2026-05-07].
Momentum
87
Value
60
Sentiment
37
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.80 · Bull $10.50 · Bear $5.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $11.29
Why
Momentum87 · Δ7d +3.1
Value60 · Δ7d -0.1
Sentiment37 · Δ7d -8.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
87
26% active weight
Current posture
7d trendFlat
Δ7d
+3.1
Δ21d
+10.7
Value
60
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
37
34% active weight
Current posture
7d trendSoftening
Δ7d
-8.1
Δ21d
-14.3
Why this grade

Composite grade B. Momentum 87.5 / Value 60.0 / Sentiment 36.9

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.48B
Beta
0.64
Shares Out
172.64M
P/E (TTM) · Derived
2529.4
P/S (TTM)
4.42
P/FCF (TTM)
117.94
Rev YoY
+38.3%
EPS YoY
-120.8%
Gross Margin
+82.5%
Op Margin
+3.7%
Net Debt
$147.06M
Current Ratio
2.12
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology